Crossmark

MiR-101-3p targets the PI3K-AKT signaling pathway via Birc5 to inhibit invasion, proliferation, and epithelial–mesenchymal transition in hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1007/s10238-025-01622-1

Published Online: 2025-03-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhu, Wenyuan

Ni, Qingqiang

Wang, Zhengjian

Zhang, Ruxuan

Liu, Fangfeng

Chang, Hong
Funding

Funding for this research was provided by:

Ethics Committee of Shandong Provincial Hospital (SWYX:NO.2022-477)
License Information

Text and Data Mining valid from 2025-03-19

Version of Record valid from 2025-03-19
More Information

Article History

Received: 17 December 2024

Accepted: 28 February 2025

First Online: 19 March 2025

Declarations

:

: The authors of this manuscript have no conflict of interest.

: The studies involving human participants were reviewed and approved by the Ethics Committee of Shandong Provincial Hospital (approval no. SWYX:NO.2022–477). All institutional and national guidelines for the care and use of laboratory animals were followed in this study.

: Not applicable.

Document is current

Any future updates will be listed below